Biopharmx Corp (NASDAQ:BPMX) fell 2.8% during trading on Tuesday . The stock traded as low as $0.28 and last traded at $0.28. 768,913 shares changed hands during trading, an increase of 13% from the average session volume of 680,539 shares. The stock had previously closed at $0.29.

Several brokerages have commented on BPMX. Roth Capital set a $3.00 target price on shares of Biopharmx Corp and gave the stock a “buy” rating in a research report on Saturday, June 3rd. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of Biopharmx Corp in a research report on Tuesday. Finally, Maxim Group restated a “buy” rating and set a $1.50 target price (down from $3.00) on shares of Biopharmx Corp in a research report on Wednesday, September 13th.

The stock’s market capitalization is $20.09 million. The stock has a 50-day moving average of $0.30 and a 200-day moving average of $0.48.

Biopharmx Corp (NASDAQ:BPMX) last announced its earnings results on Wednesday, September 13th. The company reported ($0.06) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. On average, analysts forecast that Biopharmx Corp will post ($0.25) earnings per share for the current fiscal year.

In other news, major shareholder Franklin Resources Inc bought 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was acquired at an average price of $0.34 per share, with a total value of $85,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several large investors have recently added to or reduced their stakes in BPMX. Vivo Capital LLC boosted its position in shares of Biopharmx Corp by 10.0% in the 2nd quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock valued at $6,752,000 after purchasing an additional 1,282,052 shares during the period. Vanguard Group Inc. boosted its position in shares of Biopharmx Corp by 324.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock valued at $927,000 after purchasing an additional 1,478,338 shares during the period. Finally, Virtu KCG Holdings LLC boosted its position in shares of Biopharmx Corp by 366.2% in the 2nd quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock valued at $241,000 after purchasing an additional 395,424 shares during the period.

COPYRIGHT VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/19/biopharmx-corp-bpmx-stock-price-down-2-8.html.

About Biopharmx Corp

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Stock Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related stocks with our FREE daily email newsletter.